Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fi...(beyond the control ofsanofi-aventis that...),Health

Date:5/15/2008

beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward- Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2007. Other than as required by applicable law, sanofi- aventis does not undertake any obligation to update or revise any forward- looking information or statements.

Contact:

Marisol Peron, sanofi-aventis

P: 908-981-6565

E-mail: marisol.peron@sanofi-aventis.com

Amy Ba, sanofi-aventis

P: 908-981-6563

E-mail: amy.ba@sanofi-aventis.com

'/>"/>

SOURCE sanofi-aventis Copyright©2008 PR Newswire. All rights reserved

9 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial
2. Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
3. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
4. Hospital Launches Landmark Emergency Medicine Project
5. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
6. Viatronix V3D-Colon Utilized in Another Landmark Study
7. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
8. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
9. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
10. Ceremeds OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
11. St. Jude Study Shows How T Cells Machinery Dials Down Autoimmunity